Investor Relations

2014 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/09/14KemPharm, Inc. Completes Pre-IND Meeting with FDA for NME Prodrug of Hydromorphone, KP511
Coralville, IA – December 9, 2014 – KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that it had a pre-investigational new drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) concerning KemPharm's NME prodrug of hydromorphone, KP511. The meeting, which occurred on December 4, 2014, was held with the FDA to obtain input on the pre-clinical and clinical ... 
Printer Friendly Version
12/05/14KemPharm, Inc. Receives Notice of Allowance for NME Prodrug of Methylphenidate, KP415
KP415 is Designed as an Abuse-Deterrent, Controlled Release Prodrug of Methylphenidate for the Treatment of ADHD Coralville, IA – December 5, 2014 – KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Methylphenidate-oxoacid conjugates, pr... 
Printer Friendly Version
09/30/14KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511
KemPharm's Intellectual Property Estate Now Includes Composition of Matter Patents for Two Ligand Activated Technology (LAT) Opioid Produgs – KP511 and KP201 Coralville, IA – September 30, 2014 – KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,816,083 to KemPharm for its patent applicatio... 
Printer Friendly Version
09/23/14KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada
KemPharm Joins CLADD in Support of Legislation from Health Canada to Encourage More Responsible Development and Administration of Prescription OpioidsCoralville, IA – September 23, 2014 – KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that it received a No Objection Letter (NOL) from Health Canada to begin clinical trials in Canada for its lead product candidate KP201 (... 
Printer Friendly Version
09/08/14KemPharm, Inc. Advances KP201 Clinical Program with Initiation of Human Abuse Liability and Human Gastrointestinal Motility Trials
Studies to Investigate Ability of KP201 to Deter Abuse and Reduce Opioid-Induced ConstipationCoralville, IA – September 8, 2014 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the initiation of clinical trials of KP201 designed to investigate the drug candidate's ability to deter abuse and reduce opioid-induced constipation. KP201 (benzhydrocodone hydrochloride and acetaminophen) is KemPh... 
Printer Friendly Version
08/06/14KemPharm, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference
Coralville, IA – August 6, 2014 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that President and CEO, Travis Mickle, Ph.D., will present at the Canaccord Genuity 34th Annual Growth Conference at the InterContinental Boston Hotel in Boston, MA.Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's clinical, regulatory and commercial strategy for KP201, the co... 
Printer Friendly Version
06/03/14KemPharm, Inc. Secures $60 Million Commitment from Deerfield
Multi-Tranche Financing Provides Sufficient Funding to Take KP201 Through and Beyond Potential FDA Approval and Enables KemPharm to Advance its Full Pipeline of Abuse-Deterrent ProdrugsJonathan S. Leff of Deerfield Appointed to KemPharm's Board of Directors Coralville, IA – June 3, 2014 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has entered into a $60 million financing agreem... 
Printer Friendly Version
04/30/14KemPharm, Inc. Receives Notice of Allowance for Novel Prodrug of Hydromorphone
Patent Protection for KP511 Extends KemPharm's Intellectual Property Estate for Leading Franchise of Abuse-Deterrent Opioid MedicationsCoralville, IA – April 30, 2014 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Benzoic Acid, Benzoic Acid Derivatives... 
Printer Friendly Version
04/16/14KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
Company Targets Second Quarter of 2014 to File NDA As Development Activities Accelerate North Liberty, IA – April 16, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has completed tablet manufacturing activities as part of the clinical and commercial development program for KP201. The manufactured tablets are a fixed-dose combination of KemPharm's proprietary, non-toxic ligan... 
Printer Friendly Version
03/04/14KemPharm, Inc. Expands Global Intellectual Property Estate for KP201
Composition of Matter Patents Issued in Multiple Countries for KemPharm's Lead Abuse-Deterrent Hydrocodone Prodrug Coralville, IA – March 4, 2014 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that multiple global composition of matter patents have been issued for KP201 in Russia, Ukraine, Kazakhstan, Japan, Australia, New Zealand and South Africa. Additionally, the United States Patent ... 
Printer Friendly Version
02/26/14KemPharm, Inc. to Present at Cowen and Company 34th Annual Health Care Conference
Coralville, IA – Feb. 26, 2014 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that President and CEO, Travis Mickle, Ph.D., will present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, MA.Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's development pipeline, including KP201, the company's lead c... 
Printer Friendly Version
02/05/14KemPharm, Inc. to Present at 16th Annual BIO CEO & Investor Conference
Coralville, IA – Feb. 5, 2014 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D., will present at the 16th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10-11 at the Waldorf Astoria in New York City. Among the topics to b... 
Printer Friendly Version
01/13/14KemPharm Strengthens its Board of Directors as Company Prepares for Multiple Clinical and Business Milestones in 2014
Richard Pascoe, CEO of Apricus Biosciences, and Joseph B. Saluri, Vice-President - General Counsel for Stine Seed Company, Added to KemPharm's Board Coralville, IA – Jan. 13, 2014 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the appointment of Richard Pascoe, CEO of Apricus Biosciences, and Joseph B. Saluri, Vice-President - General Counsel, Stine Seed Company, to the company's Board o... 
Printer Friendly Version
01/09/14KemPharm, Inc. to Present at Biotech Showcase™ 2014
Coralville, IA – Jan. 9, 2014 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D. will present at the Biotech Showcase™ 2014 Conference being held in San Francisco January 13-15, 2014. Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's development pipeline, including KP201, the company's lead clinical candidate for ... 
Printer Friendly Version